Business Desk: Beyond Trump’s Trade Transactions
Donald Trump, often dubbed the “Dealmaker Supervisor,” has been quite focused on trade lately. There are mentions of an arrangement with the European Union that, while not a groundbreaking achievement, could serve as leverage in ongoing tariff discussions with China.
He also took a moment to criticize India for its dealings in Russian oil and gas while expressing approval for a new agreement with Pakistan regarding investments in its oil sector. It’s interesting to think that his support for Pakistan—sometimes viewed as an extension of China’s influence—could be part of a strategy to send a strong message to Beijing.
From the Right: A Little Man’s Comfort
It’s been noted that federal courts seem to yield better outcomes, perhaps due to the political scrutiny they face. The Wall Street Journal editorial committee highlights this notion. In 2016, the Labor Bureau imposed massive fines on Sun Valley Orchard, which seemed quite excessive, almost as if the bureau was acting as prosecutor, judge, and jury.
Recently, a Court of Appeals ruling emphasized that such cases should be handled in federal courts, marking a positive step for the rights of farmers like those at Sun Valley—which, sadly, has shut down. Yet, at least now, there’s a ruling that may protect other small businesses from bureaucratic overreach.
Libertarian: Be Honest About Government Spending
A question posed by Veronique de Rugy resonates: What kind of government do we want that can fund its activities responsibly? Most folks, it seems, would be okay with paying taxes to support current government functions.
However, the burden of future costs—covering benefits and subsidies we might prefer to avoid—will likely fall on our children and grandchildren, either through higher taxes or inflation. While economic growth could, in theory, help alleviate some of these future costs, it might not be enough, especially if taxes for the wealthy aren’t raised.
The real question remains: How much government spending do we genuinely need, given our financial reality?
Liberal: Hey, End Dems – #Resistance
The ongoing democratic pushback against Trump during his second term hasn’t significantly helped the party’s reputation. Louis Teisheira points out that despite many voters’ negative views on Trump’s performance, they still prefer Republicans over Democrats.
It appears voters harbor distrust towards Democrats, making them less favorable as alternatives. Nonetheless, many Democrats continue to vocalize their #Resistance stance, which seems to benefit certain politicians by earning praise from activists and media coverage.
This trend raises questions about whether regaining control in 2026 will merely encourage these politicians to stick with the status quo rather than enact real change. It’s a curious situation.
Healthy Beat: Big Pharma Wins, Patient Loses
Dr. Vinai Prasad, who recently took a role at the FDA regarding vaccine regulations, has faced backlash and ultimately resigned after confrontations with Trump’s allies. It’s suggested that his honesty about issues surrounding Big Pharma might have been too much for the establishment.
He had previously advised Sarepta Therapeutics to halt gene therapy shipment for Duchenne muscular dystrophy, emphasizing a lack of proven patient benefit from their drug. Despite acquiring trial rights in 2016, Sarepta has yet to complete testing after nine years, all the while continuing to profit from drug sales amounting to $1.5 million annually.
In the end, it seems Big Pharma might have pushed back against Prasad for being too forthright.
